Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

8.51
-0.0501-0.59%
Volume:3.84M
Turnover:32.92M
Market Cap:8.75B
PE:-22.28
High:8.82
Open:8.40
Low:8.35
Close:8.56
52wk High:12.43
52wk Low:1.83
Shares:1.03B
Float Shares:336.00M
Volume Ratio:1.20
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3820
EPS(LYR):-0.3820
ROE:78.05%
ROA:-36.17%
PB:-17.48
PE(LYR):-22.28

Loading ...

ImmunityBio signs EU ANKTIVA distribution partnership with Accord Healthcare

Reuters
·
Feb 19

ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug

Dow Jones
·
Feb 19

Analysts Have Conflicting Sentiments on These Healthcare Companies: ImmunityBio (IBRX) and Bausch + Lomb Corporation (BLCO)

TIPRANKS
·
Feb 19

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Feb 18

ImmunityBio rises 18.3%

TIPRANKS
·
Feb 18

ImmunityBio gets Anktiva marketing authorization by European Commission

TIPRANKS
·
Feb 18

European Commission grants conditional marketing authorization for ImmunityBio ANKTIVA with BCG in NMIBC CIS

Reuters
·
Feb 18

Immunitybio Receives Authorization From the European Commission for Anktiva® With Bcg for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

THOMSON REUTERS
·
Feb 18

ImmunityBio Announces Updated Phase 2 Results for Glioblastoma Immunotherapy Trial

Reuters
·
Feb 18

Why Is ImmunityBio Stock Gaining Tuesday?

Benzinga_recent_news
·
Feb 17

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 17

S&P 500 Futures Fall In Premarket Trading; Masimo, Enlight Renewable Energy Lead

Dow Jones
·
Feb 17

ImmunityBio holds ‘productive regulatory discussions’ with SFDA in Riyadh

TIPRANKS
·
Feb 17

ImmunityBio Establishes Saudi Subsidiary to Drive MENA Expansion

Reuters
·
Feb 17

ImmunityBio CEO Discusses Company Advances in Interview

Reuters
·
Feb 17

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Feb 14

ImmunityBio call volume above normal and directionally bullish

TIPRANKS
·
Feb 06

BTIG Reaffirms Their Buy Rating on ImmunityBio (IBRX)

TIPRANKS
·
Feb 03

ImmunityBio Launches Phase 2 Trial of Chemotherapy-Free CAR-NK Cell Therapy for Indolent Lymphomas

Reuters
·
Feb 02

Immunitybio Launches Phase 2 Chemotherapy-Free Car-Nk Cell Therapy Trial With Anktiva® (Resq215b) in Indolent Lymphomas

THOMSON REUTERS
·
Feb 02